Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
It is very uncertain whether naloxone + oxycodone prolonged release tablets changes serious adverse eventsg compared with oxycodone prolonged‐released tablets (very low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether they were receiving palliative care opioid‐induced bowel dysfunction
Naloxone + oxycodone prolonged release tablets showed no clear difference in adverse events compared with oxycodone prolonged‐released tablets (low certainty).
1 finding from 1 review
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events, defined as any medical event at any dose that results in death, is life‐threatening, requires hospitalisation (or prolongation of existing hospitalisation) or results in permanent damage or disability (FDA 2016) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 50% or greater · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participant‐reported pain relief of 50% or greater during longest compared with placebo (low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
PGIC very much improved · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants reporting an adverse event · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 30% or greater · adults with painful diabetic neuropathy
It is very uncertain whether topical clonidine (TC) changes participant‐reported pain relief of 30% or greater during longest compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in much or very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
PGIC very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participants experiencing at least 1adverse event during longest compared with placebo (low certainty).
1 finding from 1 review